Update on pharmacotherapies for cholestatic liver disease.

about

Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.Primary sclerosing cholangitis: A review and update

P2860

Q55497458-63039064-3212-48E4-86E6-46D8E42F5887 Q57124621-A3FCBED7-4D13-4EB0-BD90-7ED0D55B86DC

P2860

Update on pharmacotherapies for cholestatic liver disease.

Item

http://www.wikidata.org/entity/Q55333522

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Update on pharmacotherapies for cholestatic liver disease.

@en

Update on pharmacotherapies for cholestatic liver disease.

@nl

type

Item

label

Update on pharmacotherapies for cholestatic liver disease.

@en

Update on pharmacotherapies for cholestatic liver disease.

@nl

prefLabel

Update on pharmacotherapies for cholestatic liver disease.

@en

Update on pharmacotherapies for cholestatic liver disease.

@nl

P1476

Update on pharmacotherapies for cholestatic liver disease

@en

P2093

Ahmad H Ali

http://www.w3.org/2001/XMLSchema#string

Keith D Lindor

http://www.w3.org/2001/XMLSchema#string

P2860

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies

The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population.

Primary biliary cirrhosis: a 2010 update.

Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.

P304

7-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP4.1013

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James H Tabibian

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29404429

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

5747033

http://www.w3.org/2001/XMLSchema#string

Update on pharmacotherapies for cholestatic liver disease.

about

P2860

P2860

Update on pharmacotherapies for cholestatic liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932